News stories about Heron Therapeutics (NASDAQ:HRTX) have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heron Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 93 out of 100, indicating that recent press coverage is extremely likely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s analysis:
- Heron Therapeutics, Inc. (HRTX) Rating Increased to Sell at ValuEngine (americanbankingnews.com)
- Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $4.53 Million (americanbankingnews.com)
- PerkinElmer, Inc. (PKI) is at $67.80 per share and Heron Therapeutics, Inc. (HRTX) is listed at $15.40 – Stocks Gallery (stocksgallery.com)
- Stock Price Performance Review for Heron Therapeutics, Inc. (NASDAQ:HRTX) – Jonesboro Recorder (jonesbororecorder.com)
- HSBC Upgraded Centrica PLC (LON:CNA); Heron Therapeutics (HRTX) Had 8 Bulls (frozenmail.net)
Shares of Heron Therapeutics (NASDAQ HRTX) opened at 15.05 on Friday. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00. The stock has a 50 day moving average price of $14.32 and a 200 day moving average price of $14.12.
Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million. On average, equities analysts expect that Heron Therapeutics will post ($3.70) EPS for the current fiscal year.
HRTX has been the topic of a number of recent research reports. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, May 12th. Jefferies Group LLC restated a “buy” rating and set a $29.00 price objective on shares of Heron Therapeutics in a research report on Monday, April 10th. Needham & Company LLC initiated coverage on Heron Therapeutics in a research report on Monday, February 27th. They set a “buy” rating and a $28.00 price objective on the stock. Aegis restated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, March 21st. Finally, Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 9th. Two investment analysts have rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $34.50.
In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the sale, the vice president now owns 5,250 shares of the company’s stock, valued at $80,482.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 20.31% of the stock is owned by insiders.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.